1
|
Tolino E, Skroza N, Del Giudice E, Maddalena P, Bernardini N, Proietti I, Mambrin A, Marraffa F, Rossi G, Lubrano R, Potenza C. A Case of Psoriatic Disease and Hidradenitis Suppurativa in a Child with Chromosome 17q21.31 Microduplication Syndrome. Children (Basel) 2023; 10:931. [PMID: 37371163 DOI: 10.3390/children10060931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 04/02/2023] [Accepted: 04/27/2023] [Indexed: 06/29/2023]
Abstract
Psoriatic disease is a chronic, relapsing inflammatory disorder, characterized mostly by cutaneous erythematous scaly plaques sometimes associated with arthritis. Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disease of the apocrine glands, characterized clinically by painful abscesses, sinus tracts and scars. It typically occurs after puberty, affecting mainly intertriginous areas of the body. There is a strong association between HS and psoriasis since they share the same pathogenic inflammatory pathway. The patient presented: low birthweight, microcephaly, facial dysmorphisms, lumbar hyperlordosis, walking difficulties, global psychomotor developmental delay and learning disabilities. A genetic evaluation revealed a 2.5 Mb de novo microduplication in the 17q21.31 chromosomal region. Dermatological examination revealed HS (Hurley stage II-HS) distributed in the genital area and inguinal folds, psoriatic plaques on the retroauricolar folds, on the elbows bilaterally and on the lateral aspect of the right ankle and psoriatic arthritis. The patient was treated with adalimumab, with a marked improvement of both conditions. To our best knowledge, we report the first case of coexisting Psoriatic Arthritis Disease and Hidradenitis Suppurativa in a child with chromosome 17q21.31 microduplication syndrome. We hypothesize that gene CRHR1 duplication included in the 17q21.31 chromosomal region might be involved in the pathogenesis of both diseases.
Collapse
Affiliation(s)
- Ersilia Tolino
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Nevena Skroza
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Emanuela Del Giudice
- Maternal and Child Health Department, Santa Maria Goretti Hospital, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy
| | - Patrizia Maddalena
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Nicoletta Bernardini
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Ilaria Proietti
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Alessandra Mambrin
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Federica Marraffa
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Giovanni Rossi
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| | - Riccardo Lubrano
- Maternal and Child Health Department, Santa Maria Goretti Hospital, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy
| | - Concetta Potenza
- Department of Medico-Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Via Firenze, 1, 04019 Terracina, Italy
| |
Collapse
|
2
|
Bernardini N, Skroza N, Rossi G, Mambrin A, Tolino E, Marraffa F, Caviglia M, Guardo AD, Volpe S, Proietti I, Potenza C. Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema. Dermatol Reports 2022; 14:9447. [PMID: 36483227 PMCID: PMC9724640 DOI: 10.4081/dr.2022.9447] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 09/16/2022] [Indexed: 01/21/2023] Open
Abstract
Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti-interleukin -23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psoriasis, involving primarily upper limbs, elbow, abdomen and knees (PASI 18 - DLQI 22). His medical history was relevant for epilepsy controlled pharmacologically. In addition, an eczematous and edematous appearance of the tibial area was detected; the histologic findings did not contradict the diagnostic hypothesis of subacute spongiotic dermatitis. The patient was treated with Tildrakizumab. After 12 weeks the clinical lesions improved significantly, and the eczematous component disappeared in the tibial area bilaterally. The clinical improvement was maintained even after one year of therapy. Tildrakizumab showed excellent results in the control of psoriasis, with an excellent safety profile. The promising results of clinical trials have been confirmed in a real-life setting. There are no reports about its safety in epileptic patients. In our case, neurological adverse events did not verify and tildrakizumab managed to control both the psoriatic and eczematous components.
Collapse
Affiliation(s)
- Nicoletta Bernardini
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019, Terracina (LT), Italy. +39.0773.708811.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Bernardini N, Skroza N, Prevete E, Marraffa F, Proietti I, Tolino E, Mambrin A, Rossi G, Volpe S, Bersani G, Potenza C. Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report. Dermatol Reports 2022; 14:9476. [DOI: 10.4081/dr.2022.9476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 01/26/2022] [Indexed: 11/22/2022] Open
Abstract
A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old man suffering from a severe schizophrenia, who received guselkumab (a human monoclonal antibody targeting the p40 subunit of IL-23) for the treatment of a moderate-to-severe plaque type psoriasis. After 3 months, the patient reached complete resolution of psoriasis without any side effects, maintained at 6 months follow up visit. Some studies have highlighted the hypothesis that an hyperactivation of immune response appears to be one of the main mechanisms underlying the increased risk of this association. In particular, the axis il-17/il-23 plays a central role in the pathogenesis of this disease. Further research will be needed to assess whether anti-IL23 drugs could be a more suitable therapeutic option in psoriatic patients with schizophrenia.
Collapse
|
4
|
Proietti I, Bernardini N, Skroza N, Mambrin A, Tolino E, Marchesiello A, Marraffa F, Rossi G, Volpe S, Potenza C. PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis. Rev Recent Clin Trials 2022; 17:RRCT-EPUB-124763. [PMID: 35747967 DOI: 10.2174/1574887117666220623161751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 03/16/2022] [Accepted: 04/06/2022] [Indexed: 11/22/2022]
Abstract
BACKGROUND Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology. A new self- administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding). OBJECTIVE To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis Methods: The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti- IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors). RESULTS The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement of mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies. CONCLUSION The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatments efficacy. In our study this score has been useful to put in evidence significant differences between biologic drugs.
Collapse
Affiliation(s)
- Ilaria Proietti
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Nicoletta Bernardini
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Nevena Skroza
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Alessandra Mambrin
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Ersilia Tolino
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Anna Marchesiello
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Federica Marraffa
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Giovanni Rossi
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Salvatore Volpe
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Concetta Potenza
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| |
Collapse
|
5
|
Bernardini N, Skroza N, Marraffa F, Prevete E, Mambrin A, Proietti I, Tolino E, Caviglia M, Guardo AD, Rossi G, Volpe S, Bersani G, Potenza C. A case of Twins affected by Psoriasis, Psoriatic Arthritis and Autism: Five years of efficacious and safe treatment with Secukinumab. Dermatol Ther 2022; 35:e15533. [PMID: 35460156 PMCID: PMC9539526 DOI: 10.1111/dth.15533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 04/13/2022] [Accepted: 04/20/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Nicoletta Bernardini
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Nevena Skroza
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Federica Marraffa
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Elisabeth Prevete
- Department of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, Rome, Italy
| | - Alessandra Mambrin
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Ilaria Proietti
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Ersilia Tolino
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Martina Caviglia
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Antonio Di Guardo
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Giovanni Rossi
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Salvatore Volpe
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| | - Giuseppe Bersani
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, Latina, Italy
| | - Concetta Potenza
- Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy
| |
Collapse
|
6
|
Proietti I, Borrelli I, Skroza N, Santoro PE, Gualano MR, Bernardini N, Mambrin A, Tolino E, Marchesiello A, Marraffa F, Michelini S, Rossi G, Volpe S, Ricciardi W, Moscato U, Potenza C. Adverse skin reactions to personal protective equipment (
PPE
) during
COVID
‐19 pandemic in Italian health care workers. Dermatol Ther 2022; 35:e15460. [PMID: 35306721 PMCID: PMC9111857 DOI: 10.1111/dth.15460] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 02/07/2022] [Accepted: 03/17/2022] [Indexed: 12/01/2022]
Abstract
To avoid exposure to SARS‐COV‐2, healthcare professionals must use personal protective equipment (PPE). Their use has been related to a series of adverse effects; the most frequent adverse events were headache, dyspnoea, and pressure injuries. Skin adverse effects are very common, including contact dermatitis, itching, erythema, and acneiform eruptions. The objective of this study is to evaluate the skin problems caused by personal protection equipment (PPE) in health care workers (HCWs) and to individuate eventual risk factors. From May to June 2020 a retrospective observational multi‐centric study conducted by an online survey sent by email, involving 10 hospital centers, was performed. We considered as independent variables gender and age, occupational group and sector, time of utilization, type and material of PPE. We tested 3 types of PPE: gloves, bonnet, and mask for different time of utilization (<1, 1–3, 3–6, >6 h). We performed a multiple logistic regression model to correlate them with skin adverse events occurrence. Among all the 1184 participants, 292 workers reported a dermatological pathology: 45 (15.41%) had psoriasis, 54 (18.49%) eczema, 38 (13.01%) acne, 48 (16.44%) seborrheic dermatitis, and 107 (36.64%) other. In our sample previous inflammatory dermatological conditions, female sex, prolonged use of PPE were significant risk factors for developing skin related adverse events considering all the PPE considered. The use of PPE is still mandatory in the hospital setting and skin adverse reactions still represent a global problem. Although data from Europe are limited, our study highlighted the importance of the problem of PPE skin reactions in a large sample of Italian healthcare professionals.
Collapse
Affiliation(s)
- Ilaria Proietti
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Ivan Borrelli
- Department of Health Sciences and Public Health Università Cattolica del Sacro Cuore Rome Italy
| | - Nevena Skroza
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Paolo Emilio Santoro
- Department of Woman and Child Health and Public Health Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
- Department of Health Sciences and Public Health Università Cattolica del Sacro Cuore Rome Italy
| | - Maria Rosaria Gualano
- Department of Public Health Sciences and Paediatrics University of Torino Torino Italy
| | - Nicoletta Bernardini
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Alessandra Mambrin
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Ersilia Tolino
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Anna Marchesiello
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Federica Marraffa
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Simone Michelini
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Giovanni Rossi
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Salvatore Volpe
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| | - Walter Ricciardi
- Department of Health Sciences and Public Health Università Cattolica del Sacro Cuore Rome Italy
| | - Umberto Moscato
- Department of Woman and Child Health and Public Health Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
- Department of Health Sciences and Public Health Università Cattolica del Sacro Cuore Rome Italy
- Department of Public Health Sciences and Paediatrics University of Torino Torino Italy
| | - Concetta Potenza
- Department of Medico‐Surgical Sciences and Biotechnologies Sapienza University of Rome, Polo Pontino, Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Terracina (LT) Italy
| |
Collapse
|
7
|
Bernardini N, Skroza N, Marchesiello A, Mambrin A, Proietti I, Tolino E, Maddalena P, Marraffa F, Rossi G, Volpe S, Potenza C. Psoriatic patients with a history of cancer: a real-life experience with Apremilast treatment for 104 weeks. Dermatol Ther 2022; 35:e15306. [PMID: 35100460 DOI: 10.1111/dth.15306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 12/10/2021] [Accepted: 12/28/2021] [Indexed: 11/28/2022]
Abstract
Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
Collapse
Affiliation(s)
- Nicoletta Bernardini
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Nevena Skroza
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Anna Marchesiello
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Alessandra Mambrin
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Ilaria Proietti
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Ersilia Tolino
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Patrizia Maddalena
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Federica Marraffa
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Giovanni Rossi
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Salvatore Volpe
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Concetta Potenza
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| |
Collapse
|
8
|
Proietti I, Skroza N, Mambrin A, Marraffa F, Tolino E, Bernardini N, Marchesiello A, Rossi G, Volpe S, Potenza C. Aesthetic Treatments in Cancer Patients. Clin Cosmet Investig Dermatol 2021; 14:1831-1837. [PMID: 34898993 PMCID: PMC8654687 DOI: 10.2147/ccid.s342734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 11/22/2021] [Indexed: 12/02/2022]
Abstract
Cancer patients are experiencing an increase in overall survival as a consequence of earlier diagnosis and newer effective anticancer therapies. However, cancer survivors often face long-term consequences from their original cancer diagnosis and long-term sequelae of anticancer treatment. Maintaining patients’ quality of life is of paramount importance and this can be accomplished by a multidisciplinary treatment approach, including aesthetic treatments to improve patients’ body image and positively impact their quality of life. In this perspective, we will discuss the importance of aesthetic treatments in cancer patients. In addition, we will summarise the data available regarding the use of several aesthetic treatments such as fillers, botulinum toxin and laser use in cancer patients, their safety, their efficacy, and the specific precautions that need to be implemented in this particular subset of cancer patients.
Collapse
Affiliation(s)
- Ilaria Proietti
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Nevena Skroza
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Alessandra Mambrin
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Federica Marraffa
- Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Ersilia Tolino
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Nicoletta Bernardini
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Anna Marchesiello
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Giovanni Rossi
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Salvatore Volpe
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| | - Concetta Potenza
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, 04019, Italy
| |
Collapse
|
9
|
Skroza N, Tolino E, Balduzzi V, Bernardini N, Mambrin A, Marchesiello A, Marraffa F, Rossi G, Volpe S, Proietti I, Potenza C. Advantages of Tailored Isotretinoin Treatment in Moderate to Severe Acne: Real-Life Data. Front Pharmacol 2021; 12:733526. [PMID: 34867340 PMCID: PMC8632712 DOI: 10.3389/fphar.2021.733526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 09/27/2021] [Indexed: 01/28/2023] Open
Abstract
This retrospective single-center study analyzes the efficacy and safety of isotretinoin for the treatment of moderate to severe acne in real-life clinical practice, particularly with regard to acne severity, isotretinoin cumulative dosage, and patients’ gender. The results suggest the opportunity of an early isotretinoin systemic treatment in patients affected by moderate acne and emphasize the importance of an appropriate dose adjustment in order to minimize adverse events.
Collapse
Affiliation(s)
- Nevena Skroza
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Ersilia Tolino
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Veronica Balduzzi
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | | | - Alessandra Mambrin
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Anna Marchesiello
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Federica Marraffa
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Giovanni Rossi
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Salvatore Volpe
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Ilaria Proietti
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| | - Concetta Potenza
- Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Terracina, Italy
| |
Collapse
|
10
|
Proietti I, Tolino E, Mambrin A, Skroza N, Bernardini N, Marchesiello A, Marraffa F, Michelini S, Rossi G, Volpe S, Del Giudice E, Lubrano R, Potenza C. Non-invasive instrumental examinations of cutaneous, adnexal and mucosal manifestations after SARS-COV-2 infection in adult and children. J Eur Acad Dermatol Venereol 2021; 36:e169-e170. [PMID: 34753203 PMCID: PMC9088730 DOI: 10.1111/jdv.17805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- I Proietti
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - E Tolino
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - A Mambrin
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - N Skroza
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - N Bernardini
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - A Marchesiello
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - F Marraffa
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - S Michelini
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - G Rossi
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - S Volpe
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| | - E Del Giudice
- Maternal and Child Health Department, Sapienza - University of Rome, Polo Pontino, Santa Maria Goretti Hospital, Latina, Italy
| | - R Lubrano
- Maternal and Child Health Department, Sapienza - University of Rome, Polo Pontino, Santa Maria Goretti Hospital, Latina, Italy
| | - C Potenza
- Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 'Daniele Innocenzi', Sapienza University of Rome, Polo Pontino, Italy
| |
Collapse
|
11
|
Bernardini N, Skroza N, Mambrin A, Proietti I, Marchesiello A, Marraffa F, Rossi G, Volpe S, Tolino E, Potenza C. Herpes zoster ophthalmicus in two women after Pfizer-BioNTech (BNT162b2) vaccine. J Med Virol 2021; 94:817-818. [PMID: 34585774 PMCID: PMC8661555 DOI: 10.1002/jmv.27366] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 09/21/2021] [Accepted: 09/27/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Nicoletta Bernardini
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Nevena Skroza
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Alessandra Mambrin
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Ilaria Proietti
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Anna Marchesiello
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Federica Marraffa
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Giovanni Rossi
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Salvatore Volpe
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Ersilia Tolino
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| | - Concetta Potenza
- Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy
| |
Collapse
|
12
|
Proietti I, Skroza N, Filippi L, Bernardini N, Mambrin A, Tolino E, Rossi G, Marchesiello A, Marraffa F, Volpe S, Bagni O, Potenza C. Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy. Life (Basel) 2021; 11:692. [PMID: 34357064 PMCID: PMC8307638 DOI: 10.3390/life11070692] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 07/06/2021] [Accepted: 07/08/2021] [Indexed: 12/16/2022] Open
Abstract
Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.
Collapse
Affiliation(s)
- Ilaria Proietti
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Nevena Skroza
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Luca Filippi
- Department of Nuclear Medicine, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, Italy; (L.F.); (O.B.)
| | - Nicoletta Bernardini
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Alessandra Mambrin
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Ersilia Tolino
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Giovanni Rossi
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Anna Marchesiello
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Federica Marraffa
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Salvatore Volpe
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| | - Oreste Bagni
- Department of Nuclear Medicine, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, Italy; (L.F.); (O.B.)
| | - Concetta Potenza
- Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy; (N.S.); (N.B.); (A.M.); (E.T.); (G.R.); (A.M.); (F.M.); (S.V.); (C.P.)
| |
Collapse
|
13
|
Richetta A, Marraffa F, Grassi S, Aquila E, Dybala A, Aprile F, Merli M. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report. Australas J Dermatol 2021; 62:e442-e443. [PMID: 33634474 DOI: 10.1111/ajd.13568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 12/17/2020] [Accepted: 01/04/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Antonio Richetta
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Federica Marraffa
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Sara Grassi
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Emilia Aquila
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Agnieszka Dybala
- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Francesca Aprile
- Department of Precision and Translational Medicine, Centre for the Diagnosis and Treatment of Portal Hypertension, Sapienza University of Rome, Rome, Italy
| | - Manuela Merli
- Department of Precision and Translational Medicine, Centre for the Diagnosis and Treatment of Portal Hypertension, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
14
|
Valentini V, Silvestri V, Marraffa F, Greco G, Bucalo A, Grassi S, Gagliardi A, Mazzotta A, Ottini L, Richetta AG. Gut microbiome profile in psoriatic patients treated and untreated with biologic therapy. J Dermatol 2021; 48:786-793. [PMID: 33511673 DOI: 10.1111/1346-8138.15680] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 10/09/2020] [Indexed: 01/06/2023]
Abstract
There are increasing data about the role of the gut microbiome in various autoimmune diseases, including psoriasis, a chronic inflammatory and immune-mediated disease. Current treatment strategies in psoriasis include immunomodulating biologic agents. A variable response to this type of therapy has been reported in psoriatic patients. A possible effect of biologic therapy on the gut microbiome composition has been suggested, but data are still limited. The aim of this study was to compare the gut microbiome composition between psoriatic patients treated and untreated with biologic drugs in order to identify differences which may highlight the potential impact of the treatment on the gut microbiome. 16S rRNA sequencing and bioinformatic analyses were performed on the fecal samples of 30 psoriatic patients with similar clinicopathological features, 10 of whom were undergoing biologic therapy and 20 not receiving systemic therapy. Alpha and beta diversity significantly differed between the two groups of patients. A reduced bacterial biodiversity in the group of treated patients compared with the group of untreated patients was observed. Differential relative abundances of key gut microbial communities, including Akkermansia muciniphila and Bacteroides plebeius, were identified between the two groups of patients. This study showed that biologic therapy may have an impact on the composition of the gut microbiome of psoriatic patients. Gut microbiome composition could be used as an indicator of response to therapy and the modulation of the microbial composition could help to restore the intestinal symbiosis in psoriatic patients.
Collapse
Affiliation(s)
- Virginia Valentini
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | | | - Federica Marraffa
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
| | - Giulia Greco
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
| | - Agostino Bucalo
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - Sara Grassi
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
| | - Antonella Gagliardi
- Section of Microbiology, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
| | | | - Laura Ottini
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - Antonio Giovanni Richetta
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
| |
Collapse
|
15
|
Sernicola A, Lampitelli S, Marraffa F, Maddalena P, Grassi S, Richetta AG, Calvieri S. Case Report: Cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy. F1000Res 2019; 8:933. [PMID: 32047600 PMCID: PMC6993817 DOI: 10.12688/f1000research.19149.2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/06/2019] [Indexed: 11/20/2022] Open
Abstract
We present the case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma (cSCC) of the sternal area, which was not amenable to radiation therapy (stage III, T3N0M0). The treatment history of this patient is remarkable as the disease had progressed through all lines of conventional therapy established in the literature. The patient was treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab for 35 cycles and restaged after 12 months of therapy with a whole body CT scan, documenting stage IV disease (T3N2bM1). The use of cetuximab as a single agent was effective for a limited time and we decided to initiate combination therapy with cetuximab and nivolumab. Restaging after six months of this combination regimen documented stable disease.
Collapse
Affiliation(s)
- Alvise Sernicola
- Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy
| | - Salvatore Lampitelli
- Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy
| | - Federica Marraffa
- Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy
| | - Patrizia Maddalena
- Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy
| | - Sara Grassi
- Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy
| | | | - Stefano Calvieri
- Unit of Dermatology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy
| |
Collapse
|
16
|
Richetta AG, Valentini V, Marraffa F, Paolino G, Rizzolo P, Silvestri V, Zelli V, Carbone A, Di Mattia C, Calvieri S, Frascione P, Donati P, Ottini L. Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile. Oncotarget 2018; 9:32173-32181. [PMID: 30181807 PMCID: PMC6114949 DOI: 10.18632/oncotarget.25864] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 07/13/2018] [Indexed: 11/25/2022] Open
Abstract
Background A high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, however, some patients develop metastases. Existing prognostic factors cannot reliably differentiate TM patients at risk for metastases. Objective We aimed at characterizing the clinical-pathologic and mutation profile of metastatic and not-metastatic TM in order to distinguish lesions at risk of metastases. Methods Clinical-pathologic characteristics were recorded for the TM cases analyzed. We used a Next Generation Sequencing (NGS) multi-gene panel to characterize TM for multiple somatic mutations. Results A statistically significant association emerged between the presence of metastases and Breslow thickness ≥0.6 mm (p=0.003). None of TM with lymph-node involvement had Breslow thickness <0.6 mm. Somatic mutations were identified in 19 of 21 TM analyzed (90.5%). No mutations were observed in two not-metastatic cases with the lowest Breslow thickness (≤0.4 mm), whereas mutations in more than one gene were detected in one metastatic case with the highest Breslow thickness (1.00 mm). Conclusion Our study indicates Breslow thickness ≥0.6 mm as a valid prognostic factor to distinguish TM at risk for metastases.
Collapse
Affiliation(s)
- Antonio G Richetta
- Department of Internal Medicine and Medical Specialties, Unit of Dermatology, "Sapienza" University of Rome, Rome, Italy
| | - Virginia Valentini
- Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Federica Marraffa
- Department of Internal Medicine and Medical Specialties, Unit of Dermatology, "Sapienza" University of Rome, Rome, Italy
| | - Giovanni Paolino
- Department of Internal Medicine and Medical Specialties, Unit of Dermatology, "Sapienza" University of Rome, Rome, Italy.,Unit of Dermatology and Cosmetology, IRCCS, University Vita-Salute San Raffaele, Milan, Italy
| | - Piera Rizzolo
- Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Valentina Silvestri
- Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Veronica Zelli
- Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | - Anna Carbone
- Department of Oncological and Preventative Dermatological, San Gallicano Dermatological Institute, IRCCS, Rome, Italy
| | - Cinzia Di Mattia
- Laboratory of Cutaneous Histopathology, San Gallicano Dermatologic Institute, Rome, Italy
| | - Stefano Calvieri
- Department of Internal Medicine and Medical Specialties, Unit of Dermatology, "Sapienza" University of Rome, Rome, Italy
| | - Pasquale Frascione
- Department of Oncological and Preventative Dermatological, San Gallicano Dermatological Institute, IRCCS, Rome, Italy
| | - Pietro Donati
- Laboratory of Cutaneous Histopathology, San Gallicano Dermatologic Institute, Rome, Italy
| | - Laura Ottini
- Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| |
Collapse
|